Avalanche for Shape and Feature-based Virtual Screening with 3D Alignment

Overview

Journal J Comput Aided Mol Des

Publisher Springer

Specialties Biomedical Engineering
Molecular Biology

Date 2015 Oct 14

PMID 26458937

Citations 5

Authors

David J Diller

Nancy D Connell

William J Welsh

Affiliations

Soon will be listed here.

Abstract

This report introduces a new ligand-based virtual screening tool called Avalanche that incorporates both shape- and feature-based comparison with three-dimensional (3D) alignment between the query molecule and test compounds residing in a chemical database. Avalanche proceeds in two steps. The first step is an extremely rapid shape/feature based comparison which is used to narrow the focus from potentially millions or billions of candidate molecules and conformations to a more manageable number that are then passed to the second step. The second step is a detailed yet still rapid 3D alignment of the remaining candidate conformations to the query conformation. Using the 3D alignment, these remaining candidate conformations are scored, re-ranked and presented to the user as the top hits for further visualization and evaluation. To provide further insight into the method, the results from two prospective virtual screens are presented which show the ability of Avalanche to identify hits from chemical databases that would likely be missed by common substructure-based or fingerprint-based search methods. The Avalanche method is extended to enable patent landscaping, i.e., structural refinements to improve the patentability of hits for deployment in drug discovery campaigns.

Citing Articles

QSAR-Based Computational Approaches to Accelerate the Discovery of Sigma-2 Receptor (S2R) Ligands as Therapeutic Drugs.

Yu Y, Dong H, Peng Y, Welsh W Molecules. 2021; 26(17).

PMID: 34500703 PMC: 8434483. DOI: 10.3390/molecules26175270.

Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace.

Singh N, Chaput L, Villoutreix B Brief Bioinform. 2020; 22(2):1790-1818.

PMID: 32187356 PMC: 7986591. DOI: 10.1093/bib/bbaa034.

Virtual Screening and Experimental Testing of B1 Metallo-β-lactamase Inhibitors.

Kang J, Zhang A, Faheem M, Zhang C, Ai N, Buynak J J Chem Inf Model. 2018; 58(9):1902-1914.

PMID: 30107123 PMC: 6527342. DOI: 10.1021/acs.jcim.8b00133.

MolAlign: an algorithm for aligning multiple small molecules.

Chan S J Comput Aided Mol Des. 2017; 31(6):523-546.

PMID: 28573347 DOI: 10.1007/s10822-017-0023-8.

Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.

Kimani S, Kumar S, Bansal N, Singh K, Kholodovych V, Comollo T Sci Rep. 2017; 7:43908.

PMID: 28272423 PMC: 5341070. DOI: 10.1038/srep43908.

References

Kortagere S, Chekmarev D, Welsh W, Ekins S . New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res. 2008; 25(8):1836-45. PMC: 2803117. DOI: 10.1007/s11095-008-9584-5. View

Wolber G, Seidel T, Bendix F, Langer T . Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov Today. 2008; 13(1-2):23-9. DOI: 10.1016/j.drudis.2007.09.007. View

Chekmarev D, Kholodovych V, Kortagere S, Welsh W, Ekins S . Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors. Pharm Res. 2009; 26(9):2216-24. DOI: 10.1007/s11095-009-9937-8. View

Zauhar R, Gianti E, Welsh W . Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery. J Comput Aided Mol Des. 2013; 27(12):1009-36. PMC: 3880490. DOI: 10.1007/s10822-013-9698-7. View

Hartman I, Gillies A, Arora S, Andaya C, Royapet N, Welsh W . Application of screening methods, shape signatures and engineered biosensors in early drug discovery process. Pharm Res. 2009; 26(10):2247-58. DOI: 10.1007/s11095-009-9941-z. View

Kortagere S, Welsh W . Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors. J Comput Aided Mol Des. 2006; 20(12):789-802. PMC: 2756463. DOI: 10.1007/s10822-006-9077-8. View

Giganti D, Guillemain H, Spadoni J, Nilges M, Zagury J, Montes M . Comparative evaluation of 3D virtual ligand screening methods: impact of the molecular alignment on enrichment. J Chem Inf Model. 2010; 50(6):992-1004. DOI: 10.1021/ci900507g. View

Kortagere S, Mui E, McLeod R, Welsh W . Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des. 2011; 25(5):403-11. DOI: 10.1007/s10822-011-9420-6. View

Kortagere S, Chekmarev D, Welsh W, Ekins S . Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res. 2008; 26(4):1001-11. PMC: 2836910. DOI: 10.1007/s11095-008-9809-7. View

10.

Payne D, Gwynn M, Holmes D, Pompliano D . Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2006; 6(1):29-40. DOI: 10.1038/nrd2201. View

11.

Waisser K, Bures O, Holy P, Kunes J, Oswald R, Jiraskova L . Relationship between the structure and antimycobacterial activity of substituted salicylanilides. Arch Pharm (Weinheim). 2003; 336(1):53-71. DOI: 10.1002/ardp.200390004. View

12.

Meek P, Liu Z, Tian L, Wang C, Welsh W, Zauhar R . Shape Signatures: speeding up computer aided drug discovery. Drug Discov Today. 2006; 11(19-20):895-904. DOI: 10.1016/j.drudis.2006.08.014. View

13.

Chekmarev D, Kholodovych V, Balakin K, Ivanenkov Y, Ekins S, Welsh W . Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol. 2008; 21(6):1304-14. PMC: 2758060. DOI: 10.1021/tx800063r. View

14.

Nagarajan K, Zauhar R, Welsh W . Enrichment of ligands for the serotonin receptor using the Shape Signatures approach. J Chem Inf Model. 2005; 45(1):49-57. DOI: 10.1021/ci049746x. View

15.

Kratky M, Vinsova J, Novotna E, Mandikova J, Wsol V, Trejtnar F . Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis (Edinb). 2012; 92(5):434-9. DOI: 10.1016/j.tube.2012.06.001. View

16.

Charifson P, Grillot A, Grossman T, Parsons J, Badia M, Bellon S . Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem. 2008; 51(17):5243-63. DOI: 10.1021/jm800318d. View

17.

Zauhar R, Moyna G, Tian L, Li Z, Welsh W . Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem. 2003; 46(26):5674-90. DOI: 10.1021/jm030242k. View

18.

Gwynn M, Portnoy A, Rittenhouse S, Payne D . Challenges of antibacterial discovery revisited. Ann N Y Acad Sci. 2010; 1213:5-19. DOI: 10.1111/j.1749-6632.2010.05828.x. View

19.

NOEL D, CASELY R, LINFIELD W, HARRIMAN L . Antibacterial synergism between the halogenated biphenols and the halogenated aromatic anilides and carbanilides. Appl Microbiol. 1960; 8:1-4. PMC: 1057539. DOI: 10.1128/am.8.1.1-4.1960. View

20.

Wang C, Ai N, Arora S, Erenrich E, Nagarajan K, Zauhar R . Identification of previously unrecognized antiestrogenic chemicals using a novel virtual screening approach. Chem Res Toxicol. 2006; 19(12):1595-601. PMC: 2705242. DOI: 10.1021/tx060218k. View